The new data bolster Allogene’s efforts to develop a new, easily administered cell therapy that could delay or prevent cancer recurrence.

Multiple myeloma is the second most common blood cancer in adults. It starts in the white blood cells that are responsible ...

Researchers at Umeå University have contributed new insights into how cancer cells protect themselves from cell death. The ...

Medical oncologist (ex AstraZeneca, MorphoSys, Autolus Therapeutics) joins to advance Asgard’s lead asset AT-108 into Phase 1 ...

Scientists in Canada have uncovered a surprising weakness in glioblastoma, one of the deadliest brain cancers. They found ...

A cancer drug target already being investigated in clinical trials turns out to be doing something even more consequential ...

A new study led by researchers at the University of Liège highlights the unexpected role of Stard7 in the development of intestinal cancers.

Trastuzumab pamirtecan, being developed under a 2023 partnership between BioNTech and DualityBio, elicited a 44.1% overall ...

Researchers found that pancreatic pre-cancer cells mimic dementia by forming clumps of proteins due to faulty recycling processes. These insights could shed light on why pancreatic cancer develops so ...

Senhwa Biosciences raises $16M to advance AI-powered drug discovery, accelerate cancer treatment trials, and expand machine ...